2. Search Result
Search Result
Results for "

SYK+inhibitor

" in MedChemExpress (MCE) Product Catalog:

38

Inhibitors & Agonists

3

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13518
    Piceatannol
    20+ Cited Publications

    Astringenin; trans-Piceatannol

    		 Syk Autophagy Apoptosis Endogenous Metabolite Cancer
    Piceatannol is a well-known Syk inhibitor and reduces the expression of iNOS induced by TNF. Piceatannol is an effective agent for research of acute lung injury (ALI) . Piceatannol is a naturally occurring polyphenolic stilbene found in various fruits and vegetables and exhibits anticancer and anti-inflammatory properties . Piceatannol induces apoptosis in DLBCL cell lines . Piceatannol induces autophagy and apoptosis in MOLT-4 human leukemia cells .
    Piceatannol
  • HY-15968
    Entospletinib
    10+ Cited Publications

    GS-9973

    		 Syk Cancer
    Entospletinib (GS-9973) is an orally bioavailable, selective Syk inhibitor with an IC50 of 7.7 nM.
    Entospletinib
  • HY-145598
    Sovleplenib

    HMPL-523

    		 Syk Cancer
    Sovleplenib (HMPL-523) is a highly potent, orally available and selective SYK inhibitor with an IC50 of 25 nM. Anti-tumor activity. Sovleplenib can be used for the research of immune thrombocytopenia (ITP) .
    Sovleplenib
  • HY-15323
    PRT062607 Hydrochloride
    4 Publications Verification

    P505-15 Hydrochloride

    		 Syk Mixed Lineage Kinase PAK Pyk2 FAK Apoptosis Src Cancer
    PRT062607 (P505-15) Hydrochloride is an orally available Syk inhibitor (IC50: 1 nM) that inhibits inflammation and induction Apoptosis. PRT062607 Hydrochloride exerts potent antitumor activity in tumor xenograft mouse models .
    PRT062607 Hydrochloride
  • HY-15999
    Cerdulatinib
    5+ Cited Publications

    PRT062070; PRT2070

    		 JAK Syk Cancer
    Cerdulatinib (PRT062070) is a selective Tyk2 inhibitor with an IC50 of 0.5 nM. Cerdulatinib (PRT062070) also is a dual JAK and SYK inhibitor with IC50s of 12, 6, 8 and 32 for JAK1, 2, 3 and SYK, respectively.
    Cerdulatinib
  • HY-109091
    Lanraplenib
    2 Publications Verification

    GS-9876

    		 Syk Inflammation/Immunology Cancer
    Lanraplenib (GS-9876) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib (GS-9876) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans .
    Lanraplenib
  • HY-14985
    BAY 61-3606 dihydrochloride
    5+ Cited Publications

    		 Syk Apoptosis Inflammation/Immunology Cancer
    BAY 61-3606 dihydrochloride is an orally available, ATP-competitive, reversible and highly selective Syk inhibitor with a Ki of 7.5 nM an IC50 of 10 nM . BAY 61-3606 dihydrochloride reduces ERK1/2 and Akt phosphorylation in neuroblastoma cell . BAY 61-3606 dihydrochloride induces a large decrease of Syk phosphorylation in K-rn cell lysates . Bay 61-3606 dihydrochloride sensitizes TRAIL-induced apoptosis by downregulating Mcl-1 in breast cancer cells .
    BAY 61-3606 dihydrochloride
  • HY-15322
    PRT062607
    4 Publications Verification

    P505-15; PRT-2607; BIIB-057

    		 Syk Apoptosis Caspase Inflammation/Immunology Cancer
    PRT062607 (P505-15; PRT-2607) is an orally active ATP-competitive Syk inhibitor with an IC50 value of 1 nM, and exhibits at least 80-fold selectivity over other kinases. PRT062607 blocks B cell antigen receptor-mediated activation, Fcε receptor 1-mediated basophil degranulation and microglial phagocytosis, and induces caspase-dependent apoptosis and microglial death. PRT062607 inhibits tumor growth and peripheral nerve injury-induced mechanical allodynia, and prevents neuronal loss. PRT062607 can be used in research related to rheumatoid arthritis, chronic lymphocytic leukemia, non-Hodgkin's lymphoma, neurodegenerative diseases and neuropathic pain .
    PRT062607
  • HY-12974
    PRT-060318
    4 Publications Verification

    PRT318

    		 Syk Apoptosis Inflammation/Immunology Cancer
    PRT-060318 (PRT318) s a potent, selective and orally active tyrosine kinase Syk inhibitor with an IC50 of 3 nM. PRT-060318 suppresses chronic lymphocytic leukemia (CLL) B cell activation and migration, and induces apoptosis. PRT-060318 prevents Heparin (HY-17567)-induced thrombocytopenia and thrombosis in a transgenic mouse model. PRT-060318 dihydrochloride can be used for CLL and thrombus research .
    PRT-060318
  • HY-109091B
    Lanraplenib succinate
    2 Publications Verification

    GS-9876 succinate

    		 Syk Inflammation/Immunology Cancer
    Lanraplenib succinate (GS-9876 succinate) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib succinate (GS-9876 succinate) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans .
    Lanraplenib succinate
  • HY-112390A
    Syk Inhibitor II
    2 Publications Verification

    		 Syk 5-HT Receptor Inflammation/Immunology
    Syk Inhibitor II is a potent, high selective and ATP-competitive Syk inhibitor with an IC50 of 41 nM. Syk Inhibitor II inhibits 5-HT release from RBL-cells with an IC50 of 460 nM. Syk Inhibitor II shows less potent against other kinases and has anti-allergic effect .
    Syk Inhibitor II
  • HY-12736A
    GSK143 dihydrochloride
    1 Publications Verification

    		 Syk ERK Inflammation/Immunology Cancer
    GSK143 dihydrochloride is an orally active and highly selective spleen tyrosine kinase (SYK) inhibitor with a pIC50 of 7.5. GSK143 dihydrochloride inhibits phosphorylated Erk (pErk: pIC50=7.1) . GSK143 dihydrochloride reduces inflammation and prevents recruitment of immune cells in the intestinal muscularis in mice .
    GSK143 dihydrochloride
  • HY-76474A
    BAY 61-3606 hydrochloride
    4 Publications Verification

    		 Apoptosis Syk Inflammation/Immunology Cancer
    BAY 61-3606 hydrochloride is an orally available, ATP-competitive, reversible and highly selective Syk inhibitor with a Ki of 7.5 nM and an IC50 of 10 nM . BAY 61-3606 hydrochloride reduces ERK1/2 and Akt phosphorylation in neuroblastoma cell. BAY 61-3606 hydrochloride induces a large decrease of Syk phosphorylation in K-rn cell lysates. BAY 61-3606 hydrochloride sensitizes TRAIL-induced apoptosis by downregulating Mcl-1 in breast cancer cells.
    BAY 61-3606 hydrochloride
  • HY-76474
    BAY 61-3606

    		Syk Apoptosis Inflammation/Immunology Cancer
    BAY 61-3606 is an orally available, ATP-competitive, reversible and highly selective Syk inhibitor with a Ki of 7.5 nM and an IC50 of 10 nM . BAY 61-3606 reduces ERK1/2 and Akt phosphorylation in neuroblastoma cell . BAY 61-3606 induces a large decrease of Syk phosphorylation in K-rn cell lysates . Bay 61-3606 sensitizes TRAIL-induced apoptosis by downregulating Mcl-1 in breast cancer cells .
    BAY 61-3606
  • HY-112386
    OXSI-2

    		Syk Inflammation/Immunology
    OXSI-2 is a bioavailable, cell-permeable Syk inhibitor with an EC50 of 313 nM and an IC50 of 14 nM .
    OXSI-2
  • HY-131341
    Syk-IN-4

    		Syk Inflammation/Immunology Cancer
    Syk-IN-4 is a potent, selective and orally bioavailable SYK inhibitor with an IC50 of 0.31 nM. SYK has emerged as a potential target for autoimmunity and hematological cancers .
    Syk-IN-4
  • HY-12657
    Syk-IN-1
    1 Publications Verification

    		 Syk Inflammation/Immunology
    Syk-IN-1 (compound 4) is a potent Syk inhibitor, with an IC50 of 35 nM .
    Syk-IN-1
  • HY-15324
    PRT062607 acetate
    4 Publications Verification

    P505-15 acetate; PRT-2607 acetate; BIIB-057 acetate

    		 Syk Src Mixed Lineage Kinase PAK Pyk2 FAK Apoptosis Cancer
    PRT062607 (P505-15) acetate is an orally available Syk inhibitor (IC50: 1 nM) that inhibits inflammation and induction Apoptosis. PRT062607 acetate exerts potent antitumor activity in tumor xenograft mouse models . .
    PRT062607 acetate
  • HY-112809
    GSK2646264

    		Syk Src LRRK2 GSK-3 JAK VEGFR Aurora Kinase Inflammation/Immunology
    GSK2646264 (Compound 44) is a potent and selective spleen tyrosine kinase (SYK) inhibitor with a pIC50 of 7.1. GSK2646264 also inhibits other kinases with pIC50 values of 5.4, 5.4, 5.3, 5, 4.5, <4.6 and <4.3 against LCK, LRRK2, GSK3β, JAK2, VEGFR2, Aurora B and Aurora A, respectively. GSK2646264 is penetrable into the epidermis and dermis of the skin .
    GSK2646264
  • HY-112390
    Syk Inhibitor II dihydrochloride

    		5-HT Receptor Syk Inflammation/Immunology
    Syk Inhibitor II dihydrochloride is a potent, high selective and ATP-competitive Syk inhibitor with an IC50 of 41 nM. Syk Inhibitor II dihydrochloride inhibits 5-HT release from RBL-cells with an IC50 of 460 nM. Syk Inhibitor II dihydrochloride shows less potent against other kinases and has anti-allergic effect .
    Syk Inhibitor II dihydrochloride
  • HY-124146
    BI1002494

    		Syk Inflammation/Immunology
    BI1002494 is an orally active, potent, and selective spleen tyrosine kinase (SYK) inhibitor. BI 1002494 exhibits an IC50 of 115 nM in inhibiting high-affinity IgE receptor-mediated mast cell and basophil degranulation. BI1002494 can be utilized in immunology reesearch .
    BI1002494
  • HY-12736
    GSK143

    		Syk ERK Inflammation/Immunology Cancer
    GSK143 is an orally active and highly selective spleen tyrosine kinase (SYK) inhibitor with a pIC50 of 7.5. GSK143 inhibits phosphorylated Erk (pErk: pIC50=7.1) . GSK143 reduces inflammation and prevents recruitment of immune cells in the intestinal muscularis in mice .
    GSK143
  • HY-15968R
    Entospletinib (Standard)

    GS-9973 (Standard)

    		 Syk Reference Standards Cancer
    Entospletinib (Standard) is the analytical standard of Entospletinib. This product is intended for research and analytical applications. Entospletinib (GS-9973) is an orally bioavailable, selective Syk inhibitor with an IC50 of 7.7 nM.
    Entospletinib (Standard)
  • HY-120533
    Syk-IN-11

    		Syk Inflammation/Immunology
    Syk-IN-11 (BIIB-057) is a selective Syk inhibitor with an IC50 Of 13 nM. Syk-IN-11 can be used in the study of arthritis and chronic lymphocytic leukemia .
    Syk-IN-11
  • HY-112390C
    Syk Inhibitor II hydrochloride

    		5-HT Receptor Syk Inflammation/Immunology
    Syk Inhibitor II hydrochloride is a potent, high selective and ATP-competitive Syk inhibitor with an IC50 of 41 nM. Syk Inhibitor II hydrochloride inhibits 5-HT release from RBL-cells with an IC50 of 460 nM. Syk Inhibitor II hydrochloride shows less potent against other kinases and has anti-allergic effect .
    Syk Inhibitor II hydrochloride
  • HY-155513
    Syk-IN-8

    		Syk Cancer
    Syk-IN-8 (compound 19q) is a Syk inhibitor, with antiproliferative activity against multiple hematological tumour cells. Syk-IN-8 inhibits PLCγ2 phosphorylation, can be used for research in blood cancers .
    Syk-IN-8
  • HY-112390B
    Syk Inhibitor II dihydrochloride dihydrate

    		Syk 5-HT Receptor Inflammation/Immunology
    Syk Inhibitor II dihydrochloride dihydrate is a potent, high selective and ATP-competitive Syk inhibitor with an IC50 of 41 nM. Syk Inhibitor II dihydrochloride dihydrate inhibits 5-HT release from RBL-cells with an IC50 of 460 nM. Syk Inhibitor II dihydrochloride dihydrate shows less potent against other kinases and has anti-allergic effect .
    Syk Inhibitor II dihydrochloride dihydrate
  • HY-138961
    ER-27319
    1 Publications Verification

    		 Syk Inflammation/Immunology
    ER-27319, an acridone derivative, is a potent and selective SYK inhibitor, and inhibits the tyrosine phosphorylation of SYK and its activity. ER-27319 inhibits the release of antigen-induced allergic mediators from human and rat mast cells with an IC50 of 10 μM and can be used for study in allergic diseases .
    ER-27319
  • HY-N3702
    Dehydroabietinol

    		Syk Infection Inflammation/Immunology
    Dehydroabietinol is a SYK inhibitor with an IC50 of 46.4 μM. Dehydroabietinol inhibits the growth of Trypanosoma cruzi epimastigotes, Leishmania braziliensis promastigotes and Leishmania infantum promastigotes. Dehydroabietinol indirectly inhibits the growth of Plasmodium falciparum, alters the erythrocyte membrane, and induces spherostomatocyte transformation and endovesicle formation. Dehydroabietinol can be used in studies related to immune-mediated diseases, Chagas disease, leishmaniasis and malaria .
    Dehydroabietinol
  • HY-13518R
    Piceatannol (Standard)

    Astringenin (Standard); trans-Piceatannol (Standard)

    		 Reference Standards Syk Autophagy Apoptosis Endogenous Metabolite Cancer
    Piceatannol (Standard) is the analytical standard of Piceatannol. This product is intended for research and analytical applications. Piceatannol is a well-known Syk inhibitor and reduces the expression of iNOS induced by TNF. Piceatannol is an effective agent for research of acute lung injury (ALI) . Piceatannol is a naturally occurring polyphenolic stilbene found in various fruits and vegetables and exhibits anticancer and anti-inflammatory properties . Piceatannol induces apoptosis in DLBCL cell lines . Piceatannol induces autophagy and apoptosis in MOLT-4 human leukemia cells .
    Piceatannol (Standard)
  • HY-174284
    Syk-IN-13

    		Syk Inflammation/Immunology
    Syk-IN-13 (Compound A90) is a Syk inhibitor, and can be used for research of rheumatoid arthritis and/or systemic lupus .
    Syk-IN-13
  • HY-123625
    R-348 choline

    R-932348 choline

    		 Interleukin Related JAK Syk Inflammation/Immunology
    R-348 (R-932348) choline is a potent and orally active JAK3 and Syk inhibitor. R-348 reduces IFN-γ, IL-6, and IL-10 expression. R-348 effectively diminishes acute cardiac allograft rejection .
    R-348 choline
  • HY-109091A
    Lanraplenib monosuccinate

    GS-9876 monosuccinate

    		 Syk Inflammation/Immunology Cancer
    Lanraplenib monosuccinate (GS-9876 monosuccinate) is a highly selective and orally active SYK inhibitor (IC50=9.5 nM) in development for the treatment of inflammatory diseases. Lanraplenib monosuccinate (GS-9876 monosuccinate) inhibits SYK activity in platelets via the glycoprotein VI (GPVI) receptor without prolonging bleeding time (BT) in monkeys or humans .
    Lanraplenib monosuccinate
  • HY-120214
    TAS05567

    		Syk RET Inflammation/Immunology
    TAS05567 is a potent, highly selective, ATP-competitive and orally active Syk inhibitor with an IC50 of 0.37 nM. In a panel of 192 kinases, TAS05567 only shows >70% inhibition of Syk and 4 other kinases (FLT3, JAK2, KDR and RET with IC50s of 10 nM, 4.8 nM, 600 nM and 29 nM, respectively). TAS05567 can be used for humoral immune-mediated inflammatory conditions such as autoimmune and allergic diseases .
    TAS05567
  • HY-125585
    Syk-IN-2

    		Syk Others
    Syk-IN-2 (Page 78; 35) is a spleen tyrosine kinase (Syk) inhibitor .
    Syk-IN-2
  • HY-156196
    BI 894416

    		Syk Inflammation/Immunology
    BI 894416 is a spleen tyrosine kinase (SYK) inhibitor. BI 894416 has a deuterium-labeled derivative that can be used as an internal standard for bioanalytical studies. BI 894416 is applicable to the research of severe asthma .
    BI 894416
  • HY-18911
    Type-II-IN-1

    		Syk Inflammation/Immunology
    Type-II-IN-1 (Compound 3) is a type II spleen tyrosine kinase (Syk) inhibitor with an IC50 of 2.1 nM. Type-II-IN-1 can bind to the DFG-out conformation of Syk. Type-II-IN-1 can be used for the research of immunology, such as asthma .
    Type-II-IN-1
  • HY-12974A
    PRT-060318 dihydrochloride
    4 Publications Verification

    PRT318 dihydrochloride

    		 Syk Apoptosis Inflammation/Immunology Cancer
    PRT-060318 (PRT318) dihydrochloride is a potent, selective and orally active tyrosine kinase Syk inhibitor with an IC50 of 3 nM. PRT-060318 dihydrochloride suppresses chronic lymphocytic leukemia (CLL) B cell activation and migration, and induces apoptosis. PRT-060318 dihydrochloride prevents Heparin (HY-17567)-induced thrombocytopenia and thrombosis in a transgenic mouse model. PRT-060318 dihydrochloride can be used for CLL and thrombus research .
    PRT-060318 dihydrochloride

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: